Studies on SPHK1 inhibitors have made some progress, while no ideal SPHK1 inhibitor is currently used for treating cancer in the clinic, and there are also other compounds including S1PR1 and S1PR3 (VPC03090) or S1PR2 (AB1) antagonists under preclinical evaluation [54,55]. Here, S1PR2 is linked to cancer.